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suggest that PIM is a cost-effective treatment strategy compared to OTT for HIV-1 
infected patients who have achieved sustained virological suppression.
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Objectives: Evaluate the cost associated with the ADRs from the use of boceprevir 
(BOC) or telaprevir (TLP) in patients treated with protease inhibitors (PI) in the 
SES. MethOds: A multicenter observational study of cohort ITT, extracting the nec-
essary data from the information systems of SES, from September 2012 to December 
2013, for patients treated with TLP or BOC was performed. Those co-infected patients 
(HIV or HBV), in liver transplant or with history of hepatocellular carcinoma were 
excluded. ADRs assessed were alopecia, fever, retinitis, itching, weight loss, rash, 
thrombosis, neutropenia, hemorrhoids, stomach pain, amenorrhoea, arthralgia, 
anxiety and the number of infiltrated blood received by patients. To assess the 
pharmaceutical cost of ADRs the retail price + VAT at Official List were taken, and to 
other public health costs SSPE prices, the NHS and records of unit costs were taken 
also. Results: Withdrawals caused by ADRs were higher for TLP (12.2% vs 8.1%, 
p = 0.09), frequency of pruriginous erythema (44.9% vs 4%, p < 0.001) and anemia 
(69.4 % vs. 52%, p = 0.142). For BOC, there were higher percentages of dysgeusia (16% 
vs. 0%, p = 0.011), and neutropenia (52% vs. 24.5%, p = 0.018). The results showed a 
significant difference between the treatment cost per patient associated with ADRs 
caused by BOC (€ 5,896) compared to the TLP (€ 11,234), for 34.7 weeks (BOC) and 25.9 
weeks (TLP). cOnclusiOns: In view of the results obtained, it shows that means a 
lower costs for the health system ―in the treatment of ADRs due to the use of PI in 
patients with hepatitis C― patients receiving BOC versus TLP. Postmarketing obser-
vational studies are needed to determine the actual efficacy and safety of new drugs.
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Objectives: Hepatitis C virus (HCV) treatments have been improved by the 
availability of highly effective and well-tolerated interferon-free therapies. This 
study probes the impact of such therapies on the role of primary care physicians 
(PCPs) in diagnosis, referral, and treatment of HCV patients who have historically 
been treated by gastroenterologists and hepatologists. MethOds: In the U.S., 
100 PCPs, 51 specialists (44 gastroenterologists, 7 hepatologists), and 30 Managed 
Care Organization (MCO) pharmacy directors/medical directors (PDs/MDs) were 
surveyed to assess PCP knowledge of and involvement in HCV diagnosis and 
screening, referral patterns, and treatment options. Results: Survey results 
identify referral to specialists as a notable barrier to accessing care. Some 77% 
of PCPs who follow-up with patients they refer to HCV specialists estimate that 
24% are lost to follow-up. Similarly, 73% of specialists report having PCP-referred 
patients who missed their exam, and these specialists estimate that 15% of all PCP-
referred patients “drop off”. In anticipation of multiple new HCV therapies reach-
ing the major markets, several professional societies have collaborated to develop 
expert-curated, regularly updated guidelines providing clinical recommendations 
for diagnosing and treating HCV patients (www. hcvguidelines. org). Among sur-
veyed PCPs, 74% were unaware of these guidelines; however, once informed, 63% 
of all PCP respondents indicated greater comfort with prescribing treatments rec-
ommended by these guidelines. Furthermore, 63% of MCO PDs/MDs and 98% of 
HCV specialists surveyed reported feeling more comfortable with PCPs prescribing 
these recommended treatments. cOnclusiOns: The substantial decline in the 
cascade of care from PCP referrals to specialists suggests that educating PCPs on 
new interferon-therapies presents an opportunity to maximize retention in care 
and accelerate efforts to identify undiagnosed cases. Survey responses from PCPs, 
as well as specialists, and MCO PDs/MDs suggest that practical, regularly updated 
clinical guidelines prepared by international experts could provide a common 
framework for educational outreach efforts to PCPs.
PIN113
CoverAge or effICACy: whICh fACtor Is the most INflueNtIAl for 
reduCINg vArICellA wIth routINe ChIldhood vACCINAtIoN IN ItAly?
Sauboin C.1, Holl K.1, Amodio E.2, Bonanni P.3, Gabutti G.4, Vitale F.2
1GlaxoSmithKline Vaccines, Wavre, Belgium, 2University of Palermo, Palermo, Italy, 3University of 
florence, Florence, Italy, 4University of Ferrara, Ferrara, Italy
Objectives: Policymakers may have a concern that a long time interval between 
two doses, partial efficacy and potential waning after the first dose of varicella 
vaccination would reduce the impact of a universal childhood varicella immuni-
zation program. The objective of this study is to determine the potential impact 
and relative weight of 2 key factors: (1) coverage and (2) vaccine efficacy (VE) of 
the first dose of varicella vaccination (VE-D1) in the context of long term interval 
between two doses on varicella epidemiology in Italy. MethOds: An age-structured 
dynamic transmission model is adapted and fitted to the seroprevalence of varicella 
in Italy in absence of vaccination. Vaccination is introduced with 1- and 2-dose VE, 
with long time interval between 2 doses (given at 13 months and 6 years of age). 
Several scenarios are tested including 2 levels of VE-D1 (65%/75%) and 3 coverage 
levels (95%/80%, 85%/70%, 75%/60%, respectively). Efficacy post-dose 2 is fixed at 
95%. Results: For a vaccine coverage of 95%/80%, the reduction in number of vari-
cella cases compared with the absence of vaccination for 75% and 65% VE-D1 was 
respectively 89.2%/87.5% by year 30, and 78.9%/74.6% by year 80 after vaccination 
program initiation. For a vaccine coverage of 85%/70%, the reduction in number of 
systematic differences, and conformity to malaria treatment policy, in terms of 
the use of ACT, accuracy of diagnosis, concomitant medication and cost of medi-
cation. Results: 2,171 patients’ records were analyzed. 986 (46%) were sent for 
laboratory confirmation using microscopy, out of which only 45% tested positive. 
Majority of prescriptions, 54% was on the basis of presumptive treatment. 58% of 
slide negative results received antimalarials. Gender disparity was significant; 1207 
(56%) females, 942 (43%) males. 93% of prescriptions contained ACTs with AL as the 
most frequently prescribed antimalarial drug. Monotherapy accounted for 7% of 
the prescriptions. 97% (1722) of prescriptions received at least one co-medication, 
mostly analgesics, vitamin preparations and antibiotics. Antibiotics were given to 
50% of patients, with children under five most likely to be co-prescribed antibiot-
ics. Overall, median cost of medication was US$7.34 (US$0.16 – 262.78) per case. 
There were significant variations in treatment practices between the two facili-
ties. cOnclusiOns: Evidence suggest high rate of compliance to policy on the 
use of ACT as first line treatment for uncomplicated malaria but there is significant 
scope for improved diagnosis and prescription to enhance accuracy of treatment 
and reduced wastages, especially at the medical center. Regular updates of providers 
on appropriate practices are needed to improve adherence to treatment guidelines 
for enhanced efficiency of malaria treatment in Nigeria.
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Objectives: To describe real-world treatment patterns, health care resource use, 
and opportunities for early switch (ES) from intravenous (IV) to oral antibiotics 
and early discharge (ED) for patients hospitalized in the United Arab Emirates 
(UAE) with methicillin-resistant Staphylococcus aureus (MRSA) complicated skin 
and soft-tissue infections (cSSTIs). MethOds: This retrospective observational 
medical chart review study enrolled physicians from four UAE sites to collect data 
for 24 total patients with documented MRSA cSSTI, hospitalized between July 2010-
June 2011, and discharged alive by July 2011. Data include clinical characteristics 
and outcomes, hospital length of stay (LOS), MRSA-targeted IV and oral antibiotic 
use and ES and ED eligibility using literature-based and expert-validated crite-
ria. Results: For all patients, the actual length of MRSA-active treatment was 
10.8±7 days, with 9.8±6.6 days of IV therapy, and mean LOS 13.9±9.3 days. The most 
frequent initial MRSA-active therapies used were vancomycin (33.3%), linezolid 
(16.7%), and clindamycin (16.7%). Five patients (20.8%) were switched from IV to 
oral antibiotics while inpatient. Eight patients were discharged with MRSA-active 
antibiotics, with linezolid prescribed most frequently (n= 3; 37.5%). Fifteen patients 
(62.5%) met ES criteria and potentially could have discontinued IV therapy 8.3±6.0 
days sooner. Eight patients (33.3%) met ED criteria and potentially could have 
been discharged 10.9±5.8 days earlier. Assuming an average cost of 2,691 dirhams 
($575)/bed day in the UAE, the total savings would be 29,332 dirhams ($6,268) in 
bed-day cost savings realized per ED-eligible patient. cOnclusiOns: While one 
fifth of patients were switched from IV to oral antibiotics in the UAE, there were 
clear opportunities for further optimization of health care resources. Over half of 
UAE patients hospitalized for MRSA cSSTI could be eligible for ES and one-third 
eligible for ED opportunities, resulting in the potential for a substantial reduction 
in IV days and bed days.
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Objectives: To estimate the cost-effectiveness of a strategy of switching the 
antiretroviral therapy (ART) to protease inhibitor monotherapy (PIM) with prompt 
return to combination therapy in the event of viral load rebound compared to con-
tinuing the ongoing triple therapy (OTT) in the long-term management of HIV-1 
infected patients. MethOds: Within trial cost-effectiveness analysis and modelling 
of life-time cost-effectiveness based on a randomised controlled trial of Protease 
Inhibitor monotherapy Versus Ongoing Triple-therapy (PIVOT). The setting was 
HIV outpatient care in the UK National Health Service and the trial involved 587 
patients, aged 18 years or more, who achieved sustained virological suppression 
and have a CD4+ cell count > 100 cells/mm3. Outcomes were NHS costs (2012 UK 
Pounds Sterling) and quality-adjusted life-years (QALY) with comparative results 
presented as incremental cost-effectiveness ratios (ICERs). Results: Overall, PIM 
was cost-effective compared to OTT. PIM was cost-saving due to large savings in 
the ART drug costs while being no less effective in terms of QALYs in the within 
trial analysis and only marginally less effective with modelling. In the base-case 
within-trial analysis, the incremental total cost per patient was -£6,424.11 (95% 
confidence interval: -£7,418.84 to -£5,429.38) and the incremental QALY was 0.0051 
(95% confidence interval: -0.0479 to 0.0582) making PIM dominant compared to 
OTT. Multiple sensitivity analyses were conducted to assess the importance of 
assumptions surrounding drug costs, missing data, trial protocol driven costs and 
mortality. In all sensitivity analyses, PIM was cost-saving and no marked difference 
in QALY was observed. Modelling of life time costs and QALYs showed significant 
cost-savings and marginally less effectiveness such that switching to PIM appeared 
cost-effective at accepted cost-effectiveness thresholds. cOnclusiOns: The results 
